Investigational drug · Phase 3
SJP-0132
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Dry Eye.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 26, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "SJP-0132"
First trial start
2024
Dec 30, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SJP-0132", any sponsor or status.
Conditions studied
As listed on its trial records.
- Dry Eye
Approved drugs for the same conditions: Dry eye disease · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "SJP-0132" as an intervention, largest first.
- Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye DiseasePivotal-lookingCompleted
Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd.Industry
NCT06717152 · 427 participants · Start Dec 30, 2024 · Primary completion Jul 28, 2025
Drug: SJP-0132; Placebo · For: Dry Eye
Sites: Beijing, China; Xiamen, China; Guangzhou, China · 35 sites in all
Senju Pharmaceutical Co., Ltd.Industry
NCT04139122 · 89 participants · Start Oct 5, 2019 · Primary completion Mar 3, 2020
Drug: SJP-0132; Placebo · For: Dry Eye Disease; Dry Eye Syndrome
Sites: Cypress, California
Newest research
PubMed records naming it or its code names, newest first.
- Long-Term Safety and Clinical Outcomes of Motugivatrep (SJP-0132) 0.3% Ophthalmic Suspension in Patients with Dry Eye Disease: An Open-Label, Phase 3 Study.
Hori Y, Wada T, Omatsu K · Clin Ophthalmol 2026
- Motugivatrep (SJP-0132) 0.3% Ophthalmic Suspension for Dry Eye Disease: A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 3 Trial.
Hori Y, Wada T, Omatsu K · Clin Ophthalmol 2026
- Evaluation of the skin carcinogenicity of the TRPV1 antagonist motugivatrep (SJP-0132) using an ultra-short-term two-stage skin carcinogenesis assay in Tg-rasH2 mice.
Yamagiwa Y, Kawabe M, Doi Y, et al. · J Toxicol Pathol 2026
- Results of a Randomized, Double-Masked, Placebo-Controlled Phase 1/2 Study of a TRPV1 Antagonist SJP-0132 in Participants With Dry Eye Disease.
Wada T, Omatsu K, Pflugfelder SC · Am J Ophthalmol 2026
- Efficacy and Safety of SJP-0132 in Patients With Dry Eye Disease: A Phase 2b Randomized, Double-Masked, Dose-Finding Study.
Hori Y, Wada T, Omatsu K · Am J Ophthalmol 2026
Also in development for Dry Eye
- CAM-101Elate Ocular, FD hPLPhase 31 trial
Cambium Bio Limited · Dry Eye Disease, Dry Eye, Dry Eyes Chronic
- VVN001Phase 31 trial
VivaVision Biotech, Inc · Dry Eye
- 0.25% RCI001RCI001Phase 22 trials
ORA, Inc. · Dry Eye Disease (DED), Dry Eye
- TTAX03Phase 22 trials
BioTissue Holdings, Inc · Knee Osteoarthritis, Knee Pain Chronic, Knee Arthritis
- BTV100Phase 21 trial
BioTheraVision, Inc. · Dry Eye
- VSJ-110Phase 21 trial
Vanda Pharmaceuticals · Dry Eye
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.